Millennium Management
RANI icon

Millennium Management’s Rani Therapeutics RANI Stock Holding History

Millennium Management’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$298K Buy
405,669
+242,369
+148% +$310K ﹤0.01% 5011
2025
Q4 		$220K Buy
+163,300
New +$246K ﹤0.01% 5425
2024
Q4 		– Sell
-11,447
Closed -$24.7K – 6377
2024
Q3 		$24.7K Buy
+11,447
New +$32.8K ﹤0.01% 5778
2023
Q4 		– Sell
-46,137
Closed -$100K – 6453
2023
Q3 		$100K Sell
46,137
-87,324
-65% -$334K ﹤0.01% 5337
2023
Q2 		$550K Buy
133,461
+58,893
+79% +$273K ﹤0.01% 4475
2023
Q1 		$385K Buy
74,568
+1,424
+2% +$8.56K ﹤0.01% 4751
2022
Q4 		$432K Sell
73,144
-15,990
-18% -$117K ﹤0.01% 4845
2022
Q3 		$854K Sell
89,134
-22,647
-20% -$240K ﹤0.01% 4473
2022
Q2 		$1.16M Buy
111,781
+79,256
+244% +$910K ﹤0.01% 4236
2022
Q1 		$439K Buy
+32,525
New +$540K ﹤0.01% 5227
2021
Q4 		– Sell
-28,996
Closed -$517K – 7277
2021
Q3 		$517K Buy
+28,996
New +$502K ﹤0.01% 5317

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Millennium Management's RANI Position: Q1 2026 in Review

Millennium Management increased its Rani Therapeutics (RANI) stake by 148% in Q1 2026, buying an estimated $310K and bringing the position to 405,669 shares worth $298K. The position accounts for ﹤0.01% of the portfolio, ranked #5011.

Millennium Management first reported a position in RANI in Q3 2021 and has held it in 11 quarters since. The position peaked at $1.16M in Q2 2022. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Millennium Management held 405,669 shares of Rani Therapeutics worth $298K as of Q1 2026.
  • Millennium Management bought 242,369 Rani Therapeutics shares in Q1 2026, an estimated $310K.
  • Rani Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #5011 holding.
  • Millennium Management first reported a position in Rani Therapeutics in Q3 2021 and has held it in 11 quarters since.
  • Millennium Management's Rani Therapeutics position peaked at $1.16M in Q2 2022.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.